MeSH tree: D04.210.500.054.079.065
Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced ...
Jan 15, 2026
0
11
Pharmaceutical scientists, clinicians, nurses and pharmacists from the National University of Singapore (NUS) and National University Hospital (NUH) have shown that a reduced dose of abiraterone acetate is potentially as ...
Jul 23, 2025
0
21
A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending drug abiraterone, in clinical trial results presented by scientists from UCL and the Institute ...
Jun 2, 2025
0
10
A new study finds that CivicaScript, a not-for-profit drug manufacturer in the US, can reliably supply essential generic medicines at a price that saves patients over 60%, and public and private insurers over 90%, demonstrating ...
May 21, 2025
1
25
A new editorial paper titled "Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer" has been published in Oncotarget.
Jul 17, 2024
0
26
An online pharmacy offering standardized, transparent pricing can reduce out-of-pocket costs for patients taking common medications prescribed by urologists, suggests a study in Urology Practice.
Feb 21, 2024
0
23
Medicare is the single largest provider of health insurance in the United States, serving 63.8 million senior citizens as of 2022. Three-quarters of these recipients are enrolled in optional Medicare Part D plans, which provide ...
Dec 5, 2023
0
49
For patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen deprivation therapy (ADT), and doublet therapy ...
Apr 12, 2023
0
47
